Loading...
BIOL.Q logo

BIOLASE, Inc.OTCPK:BIOL.Q Stok Raporu

Piyasa Değeri US$274.5k
Hisse Fiyatı
US$0.000001
Adil Değerim
Kullanılamıyor
1Y-92.9%
7D9.6%
1D
Portföy Değeri
​
Görünüm

BIOLASE, Inc.

OTCPK:BIOL.Q Stok Raporu

Piyasa değeri: US$274.5k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BIOLASE (BIOL.Q) Hisse Özeti

BIOLASE, Inc. iştirakleri ile birlikte Amerika Birleşik Devletleri'nde ve uluslararası alanda diş hekimleri ve hastaları için lazer sistemleri geliştirmekte, üretmekte, pazarlamakta ve satmaktadır. Daha fazla detay

BIOL.Q temel anali̇z
Kar Tanesi Skoru
Değerleme2/6
Gelecekteki Büyüme0/6
Geçmiş Performans0/6
Finansal Sağlık0/6
Temettüler0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( $274K )

Negatif hissedar öz sermayesi

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

Kazançlar son 5 yılda yılda 7.3% oranında azaldı

+ 2 daha fazla risk

BIOL.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

BIOLASE, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti BIOLASE
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$0.0097
52 Haftanın En Yüksek SeviyesiUS$0.26
52 Haftanın En Düşük SeviyesiUS$0.004
Beta0.82
1 Aylık Değişim4.28%
3 Aylık Değişim21.88%
1 Yıllık Değişim-92.93%
3 Yıllık Değişim-100.00%
5 Yıllık Değişim-100.00%
Halka arzdan bu yana değişim-100.00%

Son Haberler & Güncellemeler

Recent updates

Seeking Alpha • Aug 31

Biolase partners with dental speciality programs across U.S.

Biolase (NASDAQ:BIOL) announced strategic plan to partner with postgraduate dental specialty programs throughout North America for dentists to adopt its Waterlase technology. "We believe investing in postgraduate programs will accelerate the adoption curve and be mutually beneficial. The residents will learn the benefits of all tissue laser technology in dentistry while providing the latest in patient care," the company said. The Waterlase dental laser offers faster procedures to less invasive treatment option.
Seeking Alpha • Jul 21

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE is a name we advocate investors to steer clear of in long-only, equity focused portfolios. The company displays numerous characteristics investors are agnostic to in FY22, particularly around profitability and equity beta. BIOL's earnings model sees it print ongoing operating losses and weak FCF conversion, requiring sustained capital injections for liquidity. We've priced the stock at $4 suggesting the market has it fairly valued. We are neutral on BIOLASE, Inc. (BIOL) shares and note the company is ill-positioned to deliver capital appreciation in the coming periods. BIOL's earnings model involves razor thin gross margins that feed minimal amounts of operating income to free cash below the bottom line. Hence, it prints a series of operating losses that require continuous external capital injection in order to maintain liquidity. A review of the company's products is best left for a separate review; hence, we will take a hard data approach to gauge the investment debate. We price BIOL at $4 per share, and note it displays numerous characteristics investors are shying away from in their positioning for FY23. We rate BIOL neutral. Exhibit 1. BIOL 6-month price action Data: Updata Market factors show divergence from equity premia Investors have finally wound back the high-beta trade of FY20/21' and are paying attention to quality and value factors once more. Fundamental momentum and earnings quality are more imperative than ever. Companies with proven market fit, strong economics, and above all, defensible business models have strengthened against benchmarks whilst reducing correlations in doing so. Later we demonstrate the weakness in BIOL's earnings model. However, it's abundantly clear BIOL displays a lack of the alternative premia investors are paying a premium for in FY22. Firstly, the stock has declined in relative strength against the benchmark sharply since April, as seen below. Meanwhile, after a small blip, its equity beta has remained substantially high at 1.2 indicating it is a high-beta play that will likely to have been punished this YTD. This much is true – BIOL has caught sellers all the way from $11, posting a 59% loss since January. Exhibit 2. BIOL has weakened against the benchmark as equity beta remains high – factors investors are agnostic to in FY22 Data: Updata Unsurprisingly, the stock has also weakened against the US medical devices and health care equipment sector since equity markets began to downturn in October 2021. As seen in Exhibit 3, BIOL now trades at a 12-month low relative to the sector. As investors step up in quality and resiliency, they will look to defensible characteristics and high return on capital amid the shifting rates regime. On this, BIOL lags and hence potentially explains the relative weakness to the traditionally defensive US medtech sector. Exhibit 3. BIOL continues to weaken against US medtech & health care equipment, as investors step up in quality in the space Data: Updata Fundamental Factors Don't Stack Up Q1 FY22 sales came in at ~$10 million, ~25% YoY growth. Performance was underlined by a 43% YoY gain to US laser systems and a 35% YoY gain to BIOLASE specific procedures. International turnover also grew 15% and have been steady for the last few quarters. On a marginal basis, the company lifted gross margin 13 percentage points to 47% – above pre-pandemic gross margin of 34%. This is still razor thin however, and leaves little headroom down the P&L for margin elasticity. On this, management notes it successfully passed costs through in Q1, printing operating expenses of ~$9 million, in line from last year. To achieve is guided 10% YoY revenue growth in FY22/23', BIOL has what it calls a 3-pronged strategy that's been in situ since 2021. Chief to the first 'prong' is specialist adoption of the laser technology. To this effect, BIOL formed an academy to market the dental lasers amongst orthodontists, endodontists and periodontists back in 2021. It did this to hopefully drive up the acceleration of new accounts, management said on the Q1 earnings call. Its second 'prong' is more of a speculative growth play at the US general practitioner dentist ("GPD") market, by our estimate. It notes there are ~150,000 of these generalists in the US, and makes some very generous assumptions around its ability to penetrate this segment. Per CEO John Beaver on the Q1 earnings call, "[i]f an additional 5% of GPDs adopted our laser in the US, it would generate $225 million in laser revenue, not including consumables," on the Q1 earnings call. Again, these are very generous assumptions around its addressable market that haven't yet begun to materialise. To get to $225 million from an additional 5% of GPD adoption, BIOL says it expanded its Waterlase Exclusive Trial program. This lets GPDs utilise the system in their office for ~45 days. Included is 2 days of in-person training and mentor support, all at no extra cost. Afterwards, the clinician is prompted to buy the laser. Firstly this is a timely and costly way of trying to convert GPDs. It takes longer than 1 30 day payment cycle and there's no incentive structure to use the device on trial. Moreover, conversion has been light on these events to date. It held 30 in FY21 and 12 so far this YTD. Each had 4–8 GPDs participate, management said, 9.5%–19% participation rate. The third 'prong' is driving the adoption of its lasers to corporate dentists. It has ongoing trials with 80% of the largest DSOs in the US, which targets new graduates as many new dentists are employed by the DSOs straight from dental school. BIOL hopes to educate them on using the lasers, and try and make lasers an "essential part of their practice moving forward". Hence, when out in practice, they might be drawn to BIOL lasers. Again, fraught with assumption, by estimate, and it relies on the premise these dentists will prefer BIOL lasers in the first place. There's no evidence to suggest this will be the case. In that vein, BIOL's profitability characteristics are an equity risk looking ahead. Investors have turned away from rewarding top-line growth in FY22 and are rewarding bottom-line fundamentals and profitability instead. Whilst it continues to build its top line at ~25% YoY, this doesn't pull through the P&L to earnings and FCF. As such, BIOL has printed a series of operating losses since FY15 to date, whilst realizing a negative FCF yield across this entire time span. Moreover, sales were extremely lumpy pre-Covid, and haven't grown back past these levels. Exhibit 4. Series of lumpy sales performance and operating losses sees weak FCF conversion
Seeking Alpha • Jul 01

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE (NASDAQ:BIOL) has amended its senior secured term loan with SWK Funding LLC by extending the interest-only period of the loan by two quarters to November 2023 and reduces the minimum Consolidated Unencumbered Liquid Assets from $7,500,000 to $5,500,00. The company used a portion of the proceeds from its recent equity offering to prepay $1M of the outstanding loan balance. John Beaver, President and Chief Executive Officer of BIOLASE said, "This prepayment and amendment will result in lower interest expense while also increasing the Company's liquidity."
Seeking Alpha • Mar 21

BIOLASE: Bad News Across The Board - Sell

Company reports Q4 results in-line with preliminary numbers and provides a rather disappointing outlook. Profitability target delayed by another year. Muted growth in combination with the decision to keep pricing steady likely to result in another year of material cash usage. On the conference call, management affirmed its intent to conduct a reverse stock split before the May 23 deadline. With profitability delayed by another year and the likely requirement to raise additional capital in 2023, investors should consider selling existing positions ahead of the upcoming reverse stock split.
Analiz Makalesi • Feb 24

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jan 11

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

Company releases very strong preliminary Q4 top-line numbers with revenues now eclipsing pre-COVID numbers. Despite solid execution, shares have retreated by 80% from recent highs as investors remain wary of ongoing cash usage and a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Shares are trading at bargain levels at just 0.7x EV/Revenue. Despite poor market sentiment, highly speculative investors should consider a rebound trade in the shares given management's solid execution, bargain valuation and expectations for EBITDA profitability at the end of the year.
Seeking Alpha • Nov 24

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Company continues to outperform expectations as sales and margins recover from last year's COVID-related setback. Despite solid execution, shares have retreated by more than 70% from recent highs as investors remain wary of a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Stock looks cheap from a fundamental perspective, trading at just 1.25x EV/Revenue. On Tuesday, Biolase announced another 180-day Nasdaq extension and improved credit terms with its primary lender thus providing a major catalyst for the beaten down shares but only the most speculative investors/traders you consider scaling into the shares at current levels given ongoing cash burn and the likely requirement to execute a reverse stock split next year.

Hissedar Getirileri

BIOL.QUS Medical EquipmentUS Pazar
7D9.6%4.4%1.1%
1Y-92.9%-17.9%28.7%

Getiri vs. Endüstri: BIOL.Q geçen yıl % -17.9 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: BIOL.Q geçen yıl % 28.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BIOL.Q's price volatile compared to industry and market?
BIOL.Q volatility
BIOL.Q Average Weekly Movement33.9%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

İstikrarlı Hisse Senedi Fiyatı: BIOL.Q hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: BIOL.Q 'nin haftalık oynaklığı ( 34% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
1984157John Beaverwww.biolase.com

BIOLASE, Inc. iştirakleri ile birlikte Amerika Birleşik Devletleri'nde ve uluslararası alanda diş hekimleri ve hastaları için lazer sistemleri geliştirmekte, üretmekte, pazarlamakta ve satmaktadır. Dental lazer sistemleri diş hekimlerinin, periodontistlerin, endodontistlerin, pediatrik diş hekimlerinin, ağız cerrahlarının ve diğer diş uzmanlarının kozmetik, restoratif ve karmaşık cerrahi uygulamalar da dahil olmak üzere bir dizi minimal invaziv dental prosedürü gerçekleştirmesine olanak tanır. Şirket, yumuşak ve sert dokuları kesmek için Waterlase tüm doku dental lazer sistemleri; yumuşak doku, hijyen, geçici ağrı kesici, diş beyazlatma ve kozmetik prosedürler için diyot yumuşak doku lazer sistemleri ve cerrahi olmayan periodontitisi yönetmek ve klinik üretimi artırmak için Epic Hygiene lazer sunmaktadır.

BIOLASE, Inc. Temel Bilgiler Özeti

BIOLASE'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BIOL.Q temel i̇stati̇sti̇kler
Piyasa değeriUS$274.48k
Kazançlar(TTM)-US$15.97m
Gelir(TTM)US$46.03m
0.0x
P/S Oranı
0.0x
F/K Oranı

BIOL.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BIOL.Q gelir tablosu (TTM)
GelirUS$46.03m
Gelir MaliyetiUS$30.18m
Brüt KârUS$15.85m
Diğer GiderlerUS$31.82m
Kazançlar-US$15.97m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-0.44
Brüt Marj34.44%
Net Kâr Marjı-34.69%
Borç/Özkaynak Oranı-486.1%

BIOL.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2025/03/12 22:53
Gün Sonu Hisse Fiyatı2025/03/12 00:00
Kazançlar2024/09/30
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

BIOLASE, Inc. 8 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Edward WooAscendiant Capital Markets LLC
Bruce JacksonBenchmark Company
Kyle BauserColliers Securities